These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27624915)

  • 1. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
    Han SJ; Reis G; Kohanbash G; Shrivastav S; Magill ST; Molinaro AM; McDermott MW; Theodosopoulos PV; Aghi MK; Berger MS; Butowski NA; Barani I; Phillips JJ; Perry A; Okada H
    J Neurooncol; 2016 Dec; 130(3):543-552. PubMed ID: 27624915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.
    Saygin İ; Çakir E; Kazaz SN; Güvercin AR; Eyüpoğlu İ; Ustaoğlu MM
    Turk J Med Sci; 2024; 54(4):735-743. PubMed ID: 39295608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.
    Yeung J; Yaghoobi V; Aung TN; Vesely MD; Zhang T; Gaule P; Gunel M; Rimm DL; Chen L
    J Neuropathol Exp Neurol; 2021 Jan; 80(2):150-159. PubMed ID: 33393633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic and local immunosuppression in patients with high-grade meningiomas.
    Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
    Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
    Du Z; Abedalthagafi M; Aizer AA; McHenry AR; Sun HH; Bray MA; Viramontes O; Machaidze R; Brastianos PK; Reardon DA; Dunn IF; Freeman GJ; Ligon KL; Carpenter AE; Alexander BM; Agar NY; Rodig SJ; Bradshaw EM; Santagata S
    Oncotarget; 2015 Mar; 6(7):4704-16. PubMed ID: 25609200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression in meningiomas.
    Johnson MD
    J Clin Neurosci; 2018 Nov; 57():149-151. PubMed ID: 30153998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
    Wang S; Liechty B; Patel S; Weber JS; Hollmann TJ; Snuderl M; Karajannis MA
    J Neurooncol; 2018 May; 138(1):183-190. PubMed ID: 29427150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.
    Wang Y; Zhang C; Yan M; Ma X; Song L; Wang B; Li P; Liu P
    CNS Neurosci Ther; 2024 Jun; 30(6):e14784. PubMed ID: 38828669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the inflammatory tumor microenvironment in meningeal neoplasms.
    Berghoff AS; Kresl P; Rajky O; Widhalm G; Ricken G; Hainfellner JA; Marosi C; Birner P; Preusser M
    Clin Neuropathol; 2020; 39(6):256-262. PubMed ID: 32831157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
    Qualiotto AN; Baldavira CM; Balancin M; Ab'Saber A; Takagaki T; Capelozzi VL
    Front Immunol; 2023; 14():1268927. PubMed ID: 37901248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplexed immunofluorescence identifies high stromal CD68
    Wang J; Browne L; Slapetova I; Shang F; Lee K; Lynch J; Beretov J; Whan R; Graham PH; Millar EKA
    Sci Rep; 2021 Nov; 11(1):21608. PubMed ID: 34732817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression.
    Karimi S; Mansouri S; Mamatjan Y; Liu J; Nassiri F; Suppiah S; Singh O; Aldape K; Zadeh G
    Sci Rep; 2020 Aug; 10(1):14115. PubMed ID: 32839486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death ligand 1 and tumor-infiltrating CD8
    Zhang Y; Wang X; Shi M; Song Y; Yu J; Han S
    BMC Cancer; 2022 Nov; 22(1):1171. PubMed ID: 36371159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
    Mills AM; Peres LC; Meiss A; Ring KL; Modesitt SC; Abbott SE; Alberg AJ; Bandera EV; Barnholtz-Sloan J; Bondy ML; Cote ML; Funkhouser E; Moorman PG; Peters ES; Schwartz AG; Terry PD; Wallace K; Schildkraut JM
    Int J Gynecol Pathol; 2019 Mar; 38(2):157-170. PubMed ID: 29485423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsa_circ_0004872 mitigates proliferation, metastasis and immune escape of meningioma cells by suppressing PD-L1.
    Chen K; Huang Z; Liu C; Ouyang Q; Yan Q; Zheng W; Huang Y
    Metab Brain Dis; 2024 Jun; 39(5):895-907. PubMed ID: 38771413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review.
    Nidamanuri P; Drappatz J
    J Neurooncol; 2022 Apr; 157(2):271-276. PubMed ID: 35301639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
    Karimi S; Mansouri S; Nassiri F; Bunda S; Singh O; Brastianos PK; Dunn IF; Zadeh G
    J Neurooncol; 2021 Feb; 151(3):443-449. PubMed ID: 33611710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.